United States-based Gilead Sciences has licensed The Rockefeller University's range of broadly neutralising antibodies (bNAbs) against HIV, including the two clinical-stage agents 3BNC117 and 10-1074.
It was reported on Friday that according to the contract, Gilead Sciences has acquired exclusive global licenses to develop and commercialise Rockefeller's complete range of HIV bNAbs. Rockefeller will receive an upfront payment and is eligible to receive cumulative milestone payments, and royalties on net sales. In addition to that, the university will retain rights to perform non-clinical and early-stage clinical research on the portfolio of HIV antibodies.
The products are investigational therapies and are not approved by any regulatory body globally; their safety and efficacy have not been established. There is no cure for HIV or AIDS.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study
Precision Epigenomics partners with TruDiagnostic
Modalis partners with Ginkgo Bioworks
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002